Playing Catch-up: The FDA, Science, and Drug Regulation

[1]  Eric J Topol,et al.  Failing the public health--rofecoxib, Merck, and the FDA. , 2004, The New England journal of medicine.

[2]  Merrill Goozner,et al.  The $800 Million Pill: The Truth behind the Cost of New Drugs , 2004 .

[3]  C. Holden.  Future Brightening for Depression Treatments , 2003, Science.

[4]  M. Angell.  The Truth About the Drug Companies: How They Deceive Us and What to Do About It , 2004 .

[5]  J. Calfee.  Public Policy Issues in Direct-to-Consumer Advertising of Prescription Drugs , 2002 .

[6]  Valéria Cavalcanti Rolla,et al.  On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health , 2004 .

[7]  E. Berndt,et al.  Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process , 2004 .

[8]  Jerry Avorn,et al.  Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs , 2004 .

[9]  E Ray Dorsey,et al.  Financial anatomy of biomedical research. , 2005, JAMA.

[10]  Sam Peltzman,et al.  An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments , 1973, Journal of Political Economy.

[11]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[12]  S. Peltzman.  Regulation of pharmaceutical innovation : the 1962 amendments , 1974 .

[13]  L. Lasagna,et al.  Regulation and drug development , 1975 .

[14]  R. Litan,et al.  An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications Among Six Developed Nations , 2006 .

[15]  J. Woodcock,et al.  The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.

[16]  K. Palmer.  The Vioxx fallout. , 2005, Minnesota medicine.